

Rocio Garcia-Carbonero

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3996115/rocio-garcia-carbonero-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

206
papers

7,782
citations

42
h-index

84
g-index

225
ext. papers

9,876
ext. citations

5.2
avg, IF

5.64
L-index

#	Paper	IF	Citations
206	Position Statement on the Diagnosis, Treatment, and Response Evaluation to Systemic Therapies of Advanced Neuroendocrine Tumors, With a Special Focus on Radioligand Therapy.. <i>Oncologist</i> , 2022 , 27, e328-e339	5.7	
205	Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study.. <i>Lancet Oncology, The</i> , 2022 ,	21.7	18
204	The European Neuroendocrine Tumour Society registry, a tool to assess the prognosis of neuroendocrine neoplasms.. <i>European Journal of Cancer</i> , 2022 , 168, 80-90	7.5	0
203	VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects. 2021 , 9,		5
202	SEOM clinical guidelines for pancreatic and biliary tract cancer (2020). <i>Clinical and Translational Oncology</i> , 2021 , 23, 988-1000	3.6	7
201	Safety and activity of the TGF β receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer 2021 , 9,		29
200	Targeted Cancer Therapy: What's New in the Field of Neuroendocrine Neoplasms?. <i>Cancers</i> , 2021 , 13,	6.6	6
199	Chemotherapy in NEN: still has a role?. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021 , 22, 595-614	10.5	4
198	Description of the genetic variants identified in a cohort of patients diagnosed with localized anal squamous cell carcinoma and treated with panitumumab. <i>Scientific Reports</i> , 2021 , 11, 7402	4.9	0
197	Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2021 , 32, 439-451	10.3	30
196	Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study. <i>Annals of Oncology</i> , 2021 , 32, 600-608	10.3	25
195	INTENSIVE: InterNational rEgistry oN Sars-cov-2 positive nEuroendocrine neoplasm patients.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e16205-e16205	2.2	
194	Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2021 , 22, 665-677	21.7	24
193	Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas. <i>Clinical and Translational Oncology</i> , 2021 , 23, 1995-2019	3.6	16
192	Plasma biomarker study of lenvatinib in gastroenteropancreatic neuroendocrine tumors reveals Ang2 and FGF2 as predictors of treatment response: Results from the international phase II TALENT trial (GETNE 1509).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 4113-4113	2.2	1
191	Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-Naïve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 Trial. <i>Oncologist</i> , 2021 , 26, 941-949	5.7	3
190	Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509). <i>Journal of Clinical Oncology</i> , 2021 , 39, 2304-2312	2.2	8

189	Phase I dose-escalation study of MCLA-158, a first-in-class bispecific antibody targeting EGFR and LGR5, in metastatic colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 62-62	2.2	1
188	Usefulness of an immunohistochemical score in advanced pancreatic neuroendocrine tumors treated with CAPTEM or everolimus. <i>Pancreatology</i> , 2021 , 21, 215-223	3.8	1
187	A phase II/III randomized double-blind study of octreotide acetate LAR with axitinib versus octreotide acetate LAR with placebo in patients with advanced G1-G2 NETs of non-pancreatic origin (AXINET trial-GETNE-1107).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 360-360	2.2	6
186	Clinical Impact of Presurgery Circulating Tumor DNA after Total Neoadjuvant Treatment in Locally Advanced Rectal Cancer: A Biomarker Study from the GEMCAD 1402 Trial. <i>Clinical Cancer Research</i> , 2021 , 27, 2890-2898	12.9	9
185	Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE study. <i>European Journal of Cancer</i> , 2021 , 154, 246-252	7.5	2
184	A multicenter phase Ib/II study of DNA-PK inhibitor peposertib (M3814) in combination with capecitabine and radiotherapy in patients with locally advanced rectal cancer.. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS144-TPS144	2.2	0
183	External validity of somatostatin analogues trials in advanced neuroendocrine neoplasms: the GETNE-TRASGU study. <i>Neuroendocrinology</i> , 2021 ,	5.6	1
182	11570 A multi-cohort phase II study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origin: The DUNE trial (GETNE 1601). <i>Annals of Oncology</i> , 2020 , 31, S770-S771	10.3	15
181	Impact of Total Neoadjuvant Therapy vs. Standard Chemoradiotherapy in Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis of Randomized Trials. <i>Cancers</i> , 2020 , 12,	6.6	9
180	FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and B circulating tumour cells: the randomised phase III VISNE trial. <i>ESMO Open</i> , 2020 , 5, e000944	6	18
179	Update of the recommendations for the determination of biomarkers in colorectal carcinoma: National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology. <i>Clinical and Translational Oncology</i> , 2020 , 22, 1976-1991	3.6	7
178	Comprehensive Characterization of the Mutational Landscape in Localized Anal Squamous Cell Carcinoma. <i>Translational Oncology</i> , 2020 , 13, 100778	4.9	3
177	Oxidized lipids in the metabolic profiling of neuroendocrine tumors - Analytical challenges and biological implications. <i>Journal of Chromatography A</i> , 2020 , 1625, 461233	4.5	4
176	Genetic Profile and Functional Proteomics of Anal Squamous Cell Carcinoma: Proposal for a Molecular Classification. <i>Molecular and Cellular Proteomics</i> , 2020 , 19, 690-700	7.6	1
175	The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE-1407). <i>Oncologist</i> , 2020 , 25, 745-e1265	5.7	18
174	Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 Study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, LBA4-LBA4	2.2	115
173	Molecular correlation of the activity of evofosfamide (EVO) in combination with sunitinib (SUN) in pancreatic Neuroendocrine Tumors (pNETs) in the SUNEVO GETNE Trial.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e16706-e16706	2.2	
172	Epigenetic Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas. <i>Clinical Cancer Research</i> , 2020 , 26, 902-909	12.9	13

171	Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECURSE and J003 trials. <i>Annals of Oncology</i> , 2020 , 31, 88-95	10.3	18
170	VITAL phase 2 study: Upfront 5-fluorouracil, mitomycin-C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09-02). <i>Cancer Medicine</i> , 2020 , 9, 1008-1016	4.8	5
169	SARS-CoV-2-related pneumonia can be successfully managed in patients with metastatic neuroendocrine tumors: a critical point of view. <i>Endocrine</i> , 2020 , 70, 6-10	4	2
168	Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. <i>New England Journal of Medicine</i> , 2020 , 383, 2207-2218	59.2	455
167	Effect of Aflibercept Plus Modified FOLFOX6 Induction Chemotherapy Before Standard Chemoradiotherapy and Surgery in Patients With High-Risk Rectal Adenocarcinoma: The GEMCAD 1402 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2019 , 5, 1566-1573	13.4	17
166	Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study). <i>British Journal of Cancer</i> , 2019 , 121, 537-544	8.7	8
165	Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy. <i>Annals of Oncology</i> , 2019 , 30, 439-446	10.3	14
164	TGF β receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2019 , 83, 975-991	3.5	36
163	Economics of gastroenteropancreatic neuroendocrine tumors: a systematic review. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2019 , 10, 2042018819828217	4.5	5
162	Combination of KIR2DS4 and FcRIIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer. <i>Scientific Reports</i> , 2019 , 9, 2589	4.9	6
161	Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR Study. <i>Oncologist</i> , 2019 , 24, 38-46	5.7	16
160	Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2571-2580	2.2	28
159	SUNITinib with EVOfosfamide (TH-302) for G1/G2 metastatic pancreatic neuroendocrine tumours (pNETs) naïve for systemic treatment. The SUNEVO phase II trial of the Spanish task force group for neuroendocrine and endocrine tumours (GETNE). <i>Annals of Oncology</i> , 2019 , 30, v566	10.3	2
158	The correlation between immune subtypes and consensus molecular subtypes in colorectal cancer identifies novel tumour microenvironment profiles, with prognostic and therapeutic implications. <i>European Journal of Cancer</i> , 2019 , 123, 118-129	7.5	23
157	Randomized phase III study comparing FOLFOX + bevacizumab versus folfoxiri + bevacizumab (BEV) as 1st line treatment in patients with metastatic colorectal cancer (mCRC) with β baseline circulating tumor cells (bCTCs).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3507-3507	2.2	13
156	The SUNEVO (GETNE-1408) trial to evaluate the activity and safety of the combination of sunitinib with evofosfamide (TH-302) in patients with G1/G2 metastatic pancreatic neuroendocrine tumours (pNETs) naïve for systemic treatment: A phase II study of the Spanish Task Force Group for Neuroendocrine and Endocrine Tumours (GETNE). <i>Journal of Clinical Oncology</i> , 2019 , 37, 4105-4105	2.2	5
155	A phase Ib dose-escalation and cohort-expansion study of safety and activity of the transforming growth factor (TGF) β receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4124-4124	2.2	22
154	Systemic administration of the hyaluronidase-expressing oncolytic adenovirus VCN-01 in patients with advanced or metastatic pancreatic cancer: First-in-human clinical trial. <i>Annals of Oncology</i> , 2019 , 30, v271-v272	10.3	7

153	Exploratory findings from a prematurely closed international, multicentre, academic trial: RAVELLO, a phase III study of regorafenib versus placebo as maintenance therapy after first-line treatment in RAS wild-type metastatic colorectal cancer. <i>ESMO Open</i> , 2019 , 4, e000519	6	3
152	Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma. <i>Oncologist</i> , 2019 , 24, 1375-1383	5.7	16
151	Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study. <i>Oncologist</i> , 2019 , 24, 185-192	5.7	52
150	Unmet Needs in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3). <i>Neuroendocrinology</i> , 2019 , 108, 54-62	5.6	41
149	Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study. <i>Annals of Oncology</i> , 2019 , 30, 124-131	10.3	29
148	SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2018). <i>Clinical and Translational Oncology</i> , 2019 , 21, 55-63	3.6	9
147	HER2-targeted therapy: an emerging strategy in advanced colorectal cancer. <i>Expert Opinion on Investigational Drugs</i> , 2019 , 28, 29-38	5.9	16
146	Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial. <i>Endocrine-Related Cancer</i> , 2018 , 25, 309-322	5.7	77
145	Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE). <i>Oncologist</i> , 2018 , 23, 422-432	5.7	45
144	Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study. <i>Annals of Oncology</i> , 2018 , 29, 602-609	10.3	61
143	Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: exploratory analyses of the RAISE trial and validation in an electronic medical record data set. <i>ESMO Open</i> , 2018 , 3, e000347	6	13
142	Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer. <i>Annals of Oncology</i> , 2018 , 29, 119-126	10.3	46
141	The safety of trifluridine and tipiracil for the treatment of metastatic colorectal cancer. <i>Expert Opinion on Drug Safety</i> , 2018 , 17, 643-650	4.1	2
140	Assessing prognosis of neuroendocrine neoplasms: Results of a collaborative multinational effort including over 10.000 european patients in the ENETS registry. <i>Journal of Clinical Oncology</i> , 2018 , 36, 4095-4095	2.2	2
139	Phase II study of panitumumab, 5-fluorouracil, mitomycin-c and radiotherapy treatment in patients with non-metastatic squamous cell carcinoma of the anal canal: safety and efficacy results (VITAL study) GEMCAD 09-02. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3566-3566	2.2	
138	Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naive Advanced Pancreatic Neuroendocrine Tumors. <i>Oncologist</i> , 2018 , 23, 766-e90	5.7	38
137	Prognostic and predictive biomarkers for somatostatin analogs, peptide receptor radionuclide therapy and serotonin pathway targets in neuroendocrine tumours. <i>Cancer Treatment Reviews</i> , 2018 , 70, 209-222	14.4	8
136	Efficacy of lenvatinib in patients with advanced pancreatic (panNETs) and gastrointestinal (giNETs) grade 1/2 (G1/G2) neuroendocrine tumors: Results of the international phase II TALENT trial (GETNE 1509). <i>Annals of Oncology</i> , 2018 , 29, viii467	10.3	13

135	Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer. <i>British Journal of Cancer</i> , 2018 , 119, 1208-1214	8.7	111
134	SEOM/SERAM consensus statement on radiological diagnosis, response assessment and follow-up in colorectal cancer. <i>Clinical and Translational Oncology</i> , 2017 , 19, 135-148	3.6	1
133	The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review. <i>Oncologist</i> , 2017 , 22, 272-285	5.7	14
132	Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer. <i>Oncologist</i> , 2017 , 22, 375-e30	5.7	17
131	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2017 , 105, 245-254	5.6	69
130	Optimization of Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2017 , 16, 1999-2007	6.1	8
129	Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial. <i>European Journal of Cancer</i> , 2017 , 78, 61-69	7.5	21
128	Prognostic relevance of Src activation in stage II-III colon cancer. <i>Human Pathology</i> , 2017 , 67, 119-125	3.7	9
127	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms. Systemic Therapy 2: Chemotherapy. <i>Neuroendocrinology</i> , 2017 , 105, 281-294	5.6	66
126	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Biotherapy and Novel Targeted Agents. <i>Neuroendocrinology</i> , 2017 , 105, 266-280	5.6	82
125	Safety and efficacy of nintedanib for the treatment of metastatic colorectal cancer. <i>Expert Opinion on Investigational Drugs</i> , 2017 , 26, 1295-1305	5.9	3
124	Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection 2017 , 5, 71		77
123	Optimizing Somatostatin Analog Use in Well or Moderately Differentiated Gastroenteropancreatic Neuroendocrine Tumors. <i>Current Oncology Reports</i> , 2017 , 19, 72	6.3	9
122	Exposure-response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2017 , 80, 599-608	3.5	12
121	Design and Validation of the GI-NEC Score to Prognosticate Overall Survival in Patients With High-Grade Gastrointestinal Neuroendocrine Carcinomas. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	18
120	Proxies of quality of life in metastatic colorectal cancer: analyses in the RECOURSE trial. <i>ESMO Open</i> , 2017 , 2, e000261	6	16
119	Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial. <i>Clinical and Translational Oncology</i> , 2017 , 19, 227-235	3.6	18
118	Translational research in neuroendocrine tumors: pitfalls and opportunities. <i>Oncogene</i> , 2017 , 36, 1899-1907	3.7	20

117	Compassionate use program with FDT-TPI (trifluridine-tipiracil) in pre-treated metastatic colorectal cancer patients: Spanish real world data.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e15019-e15019	2.2	6
116	A multicohort phase II study of durvalumab plus tremelimumab for the treatment of patients (PTS) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic (GEP) or lung origin (the DUNE trial-GETNE1601-).. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS4146-TPS4146	2.2	2
115	Onset of neutropenia as an indicator of treatment response in the phase 3 RECURSE trial of trifluridine/tipiracil (TAS-102) versus placebo in patients with metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 775-775	2.2	8
114	Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression. <i>Annals of Oncology</i> , 2016 , 27, 2082-2090	10.3	40
113	Management of controversial gastroenteropancreatic neuroendocrine tumour clinical situations with somatostatin analogues: results of a Delphi questionnaire panel from the NETPraxis program. <i>BMC Cancer</i> , 2016 , 16, 858	4.8	6
112	ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas. <i>Neuroendocrinology</i> , 2016 , 103, 186-94	5.6	324
111	TAS-102 versus placebo plus best supportive care in patients with metastatic colorectal cancer refractory to standard therapies: Final survival results of the phase III RECURSE trial.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 634-634	2.2	8
110	TAS-102 versus placebo (PBO) in patients (pts) ≥5 years (y) with metastatic colorectal cancer (mCRC): An age-based analysis of the recourse trial.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 638-638	2.2	2
109	Phase III RECURSE trial of TAS-102 versus placebo with best supportive care in patients with metastatic colorectal cancer: Geographic subgroups.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 646-646	2.2	6
108	A phase II trial to assess the activity and safety of the hypoxia-activated prodrug evofosfamide (TH-302) in combination with sunitinib in patients with disseminated grade 1 and 2 pancreatic neuroendocrine tumors (pNET) as a first-line approach: The GETNE-1408 trial.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS479-TPS479	2.2	2
107	Comparison of three molecular methods to detect mutations in KRAS, NRAS, BRAF and PIK3CA in metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3559-3559	2.2	
106	Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src. <i>Oncotarget</i> , 2016 , 7, 33111-24	3.3	22
105	Well-Differentiated Grade 2, Type 3 Gastrointestinal Neuroendocrine Tumour with Bilateral Metastatic Ovarian Involvement: Report of an Unusual Case. <i>Case Reports in Oncology</i> , 2016 , 9, 255-61	1	4
104	Ramucirumab Clinical Development: an Emerging Role in Gastrointestinal Tumors. <i>Targeted Oncology</i> , 2016 , 11, 479-87	5	3
103	Is regorafenib providing clinically meaningful benefits to pretreated patients with metastatic colorectal cancer?. <i>Clinical and Translational Oncology</i> , 2016 , 18, 1072-1081	3.6	5
102	The safety and efficacy of ramucirumab for the treatment of metastatic colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2016 , 16, 585-95	3.5	5
101	Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE). <i>Annals of Oncology</i> , 2015 , 26, 1987-1993 ^{10.3}		85
100	Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. <i>Lancet Oncology</i> , 2015 , 16, 488-500	21.7	568

99	Randomized trial of TAS-102 for refractory metastatic colorectal cancer. <i>New England Journal of Medicine</i> , 2015 , 372, 1909-19	59.2	720
98	Guidelines for diagnosis, staging and treatment of metastatic colorectal cancer by Grupo Español Multidisciplinar en Cancer Digestivo (GEMCAD). <i>Colorectal Cancer</i> , 2015 , 4, 97-112	0.8	
97	Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors. <i>Cancer and Metastasis Reviews</i> , 2015 , 34, 381-400	9.6	40
96	O-020 Quality-of-life results from RAISE: randomized, double-blind phase III study of FOLFIRI plus ramucirumab or placebo in patients with metastatic colorectal carcinoma after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. <i>Annals of Oncology</i> , 2015 , 26, iv115	10.3	4
95	2139 CONSIGN: An open-label phase 3B study of regorafenib in patients with metastatic colorectal cancer (mCRC) who failed standard therapy. <i>European Journal of Cancer</i> , 2015 , 51, S378-S379	7.5	9
94	LBA-05 Results from the large, open-label phase 3b CONSIGN study of regorafenib in patients with previously treated metastatic colorectal cancer. <i>Annals of Oncology</i> , 2015 , 26, iv118	10.3	22
93	El c�ncer colorrectal en la mujer. <i>Arbor</i> , 2015 , 191, a236	0.2	
92	Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer. <i>Cancer Discovery</i> , 2015 , 5, 598-609	24.4	65
91	SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer 2015. <i>Clinical and Translational Oncology</i> , 2015 , 17, 972-81	3.6	21
90	Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETS): current perspectives and future trends of an exciting field in development. <i>Cancer and Metastasis Reviews</i> , 2015 , 34, 823-42	9.6	30
89	Actualizaci�n de la recomendaci�n para la determinaci�n de biomarcadores en el carcinoma colorrectal. Consenso Nacional de la Sociedad Espa�ola de Anatom�a Patol�gica y de la Sociedad Espa�ola de Oncolog�a M�dica. <i>Revista Espanola De Patologia</i> , 2015 , 48, 14-24	1.2	1
88	Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. <i>Clinical and Translational Oncology</i> , 2015 , 17, 264-73	3.6	7
87	RAISE: A randomized, double-blind, multicenter phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab (RAM) or placebo (PBO) in patients (pts) with metastatic colorectal carcinoma (CRC) progressive during or following first-line combination therapy with bevacizumab (bev), oxaliplatin (ox), and a fluoropyrimidine (fp).. <i>Journal of Clinical Oncology</i> , 2015 ,	2.2	8
86	Gene expression profile predictive of response to chemotherapy in metastatic colorectal cancer. <i>Oncotarget</i> , 2015 , 6, 6151-9	3.3	17
85	Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2014 , 73, 695-702	3.5	23
84	Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma. <i>Cancer</i> , 2014 , 120, 454-6	6.4	3
83	GATA4 loss in the septum transversum mesenchyme promotes liver fibrosis in mice. <i>Hepatology</i> , 2014 , 59, 2358-70	11.2	37
82	SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) 2014. <i>Clinical and Translational Oncology</i> , 2014 , 16, 1025-34	3.6	17

81	Systemic therapeutic strategies for GEP-NETS: what can we expect in the future?. <i>Cancer and Metastasis Reviews</i> , 2014 , 33, 367-72	9.6	9
80	Molecular biology of neuroendocrine tumors: from pathways to biomarkers and targets. <i>Cancer and Metastasis Reviews</i> , 2014 , 33, 345-51	9.6	24
79	MicroRNA clusters: dysregulation in lung adenocarcinoma and COPD. <i>European Respiratory Journal</i> , 2014 , 43, 1740-9	13.6	73
78	A critical review of HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and beyond. <i>Cancer Letters</i> , 2014 , 351, 30-40	9.9	50
77	Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma. <i>European Journal of Cancer</i> , 2014 , 50, 496-505	7.5	24
76	Clinical management of regorafenib in the treatment of patients with advanced colorectal cancer. <i>Clinical and Translational Oncology</i> , 2014 , 16, 942-53	3.6	21
75	Prognostic relevance of estrogen receptor- β Ser167 phosphorylation in stage II-III colon cancer patients. <i>Human Pathology</i> , 2014 , 45, 2437-46	3.7	9
74	MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer. <i>BMC Cancer</i> , 2014 , 14, 656	4.8	55
73	An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer. <i>Oncologist</i> , 2014 , 19, 350-1	5.7	46
72	Guidelines for biomarker testing in gastroenteropancreatic neuroendocrine neoplasms: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. <i>Clinical and Translational Oncology</i> , 2014 , 16, 243-56	3.6	7
71	Phase II trial of panitumumab (P) plus mytomicin C (M), 5-fluorouracil (5-FU), and radiation (RT) in patients with squamous cell carcinoma of the anal canal (SCAC): Safety and efficacy profile VITAL study, GEMCAD 09-02 clinical trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4034-4034	2.2	2
70	Correlation of VEGFR2 expression in tumor tissue with longer progression-free survival in patients with neuroendocrine tumors (NETs) treated with pazopanib.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e15154-e15154	2.2	1
69	Concordance of ColoPrint and MSI-print classification in paired endoscopic-surgical specimens of stage I-III colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 501-501	2.2	1
68	MicroRNA-dependent regulation of transcription in non-small cell lung cancer. <i>PLoS ONE</i> , 2014 , 9, e90524	3.7	53
67	Pazopanib activity in pancreatic neuroendocrine tumors (pNETs).. <i>Journal of Clinical Oncology</i> , 2014 , 32, e15171-e15171	2.2	
66	A phase 1 mechanism of action study of intratumoral or intravenous administration of enadenotucirev, an oncolytic Ad11/Ad3 chimeric group B adenovirus in colon cancer patients undergoing resection of primary tumor.. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS3112-TPS3112	2.2	
65	New Anticancer Agents in Neuroendocrine Tumors 2014 , 181-198		
64	Identification of proteomic signatures associated with lung cancer and COPD. <i>Journal of Proteomics</i> , 2013 , 89, 227-37	3.9	94

63	Inhibition of HSP90 molecular chaperones: moving into the clinic. <i>Lancet Oncology, The</i> , 2013 , 14, e358-62.	1.7	263
62	SEOM clinical guidelines for the treatment of advanced colorectal cancer 2013. <i>Clinical and Translational Oncology</i> , 2013 , 15, 996-1003	3.6	17
61	Recomendaciones para la Determinación de Biomarcadores en Tumores Endocrinos Gastroenteropancreáticos. Consenso nacional de la Sociedad Española de Anatomía Patológica y de la Sociedad Española de Oncología Médica. <i>Revista Espanola De Patologia</i> , 2013 , 46, 222-236	1.2	2
60	Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: a phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801). <i>European Journal of Cancer</i> , 2013 , 49, 3780-7	7.5	74
59	Epithelial-mesenchymal transition markers in the differential diagnosis of gastroenteropancreatic neuroendocrine tumors. <i>American Journal of Clinical Pathology</i> , 2013 , 140, 61-72	1.9	32
58	Prognostic factors and long-term outcome of pancreatic neuroendocrine neoplasms: Ki-67 index shows a greater impact on survival than disease stage. The large experience of the Spanish National Tumor Registry (RGETNE). <i>Neuroendocrinology</i> , 2013 , 98, 156-68	5.6	53
57	Identification of oxidative stress related proteins as biomarkers for lung cancer and chronic obstructive pulmonary disease in bronchoalveolar lavage. <i>International Journal of Molecular Sciences</i> , 2013 , 14, 3440-55	6.3	29
56	The European medicines agency review of abiraterone for the treatment of metastatic castration-resistant prostate cancer in adult men after docetaxel chemotherapy and in chemotherapy-naïve disease: summary of the scientific assessment of the committee for medicinal products for human use. <i>Oncologist</i> , 2013 , 18, 1632-42	5.7	11
55	DICER1, DROSHA and miRNAs in patients with non-small cell lung cancer: implications for outcomes and histologic classification. <i>Carcinogenesis</i> , 2013 , 34, 1031-8	4.6	42
54	Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial. <i>Clinical Cancer Research</i> , 2013 , 19, 2541-50	12.9	61
53	Spinophilin loss correlates with poor patient prognosis in advanced stages of colon carcinoma. <i>Clinical Cancer Research</i> , 2013 , 19, 3925-35	12.9	13
52	Targeting tyrosine kinase receptors in hepatocellular carcinoma. <i>Current Cancer Drug Targets</i> , 2013 , 13, 300-12	2.8	34
51	Proof-of-concept study of Sym004, an anti-EGFR monoclonal antibody (mAb) mixture, in patients (pts) with anti-EGFR mab-refractory KRAS wild-type (wt) metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3551-3551	2.2	5
50	Pimasertib plus gemcitabine in metastatic pancreatic adenocarcinoma: Results of a safety run-in part of a phase II trial.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4041-4041	2.2	3
49	sVEGFR2 and circulating tumor cells to predict for the efficacy of pazopanib in neuroendocrine tumors (NETs): PAZONET subgroup analysis.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4140-4140	2.2	8
48	Phase II study to evaluate efficacy and safety of irinotecan, capecitabine, and bevacizumab in metastatic colorectal cancer (mCRC) patients.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 501-501	2.2	0
47	Long-term efficacy and pharmacodynamic parameter analysis in pretreated KRAS-mutant metastatic colorectal carcinoma (mCRC) patients treated with RG7160 (GA201), an antibody-dependent cellular cytotoxicity (ADCC)-enhanced monoclonal anti-EGFR antibody.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 379-379	2.2	
46	Microarray gene expression study of the RESPECT trial for the identification of prognostic and predictive markers.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e14561-e14561	2.2	

45	Recomendación para la determinación de biomarcadores en el carcinoma colorrectal. Consenso Nacional de la Sociedad Española de Anatomía Patológica y de la Sociedad Española de Oncología Médica. <i>Revista Espanola De Patologia</i> , 2012 , 45, 130-144	1.2	3
44	Guidelines for biomarker testing in colorectal carcinoma (CRC): a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM). <i>Clinical and Translational Oncology</i> , 2012 , 14, 726-39	3.6	18
43	PDGFR α and VEGFR2 polymorphisms in colorectal cancer: incidence and implications in clinical outcome. <i>BMC Cancer</i> , 2012 , 12, 514	4.8	10
42	A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer. <i>Clinical and Translational Oncology</i> , 2012 , 14, 606-12	3.6	17
41	Pazonet: A Phase II Trial of Pazopanib as a Sequencing Treatment in Progressive Metastatic Neuroendocrine Tumors (NETS) Patients (PTS), On Behalf of The Spanish Task Force for Nets (GETNE). <i>Annals of Oncology</i> , 2012 , 23, ix377	10.3	3
40	New targeted agents in gastroenteropancreatic neuroendocrine tumors. <i>Targeted Oncology</i> , 2012 , 7, 99-106	5	8
39	SEOM clinical guidelines for the diagnosis and treatment of gastric adenocarcinoma. <i>Clinical and Translational Oncology</i> , 2012 , 14, 528-35	3.6	13
38	PAZONET: Results of a phase II trial of pazopanib as a sequencing treatment in progressive metastatic neuroendocrine tumors (NETs) patients (pts), on behalf of the Spanish task force for NETs (GETNE). <i>Journal of Clinical Oncology</i> , 2012 , 30, 4119-4119	2.2	5
37	The GAIN-C study (BP25438): Randomized phase II trial of RG7160 (GA201) plus FOLFIRI, compared to cetuximab plus FOLFIRI or FOLFIRI alone in second-line KRAS wild type (WT) or mutant metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, TPS3637-TPS3637	2.2	3
36	Pax8 detection in well-differentiated pancreatic endocrine tumors: how reliable is it?. <i>American Journal of Surgical Pathology</i> , 2011 , 35, 1906-8	6.7	15
35	Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors. <i>Cancer and Metastasis Reviews</i> , 2011 , 30 Suppl 1, 19-26	9.6	35
34	Immunohistochemical assessment of Pax8 expression during pancreatic islet development and in human neuroendocrine tumors. <i>Histochemistry and Cell Biology</i> , 2011 , 136, 595-607	2.4	55
33	Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer. <i>Clinical and Translational Oncology</i> , 2011 , 13, 179-84	3.6	67
32	SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours (GEP NETS). <i>Clinical and Translational Oncology</i> , 2011 , 13, 545-51	3.6	9
31	Recommendations and expert opinion on the adjuvant treatment of colon cancer in Spain. <i>Clinical and Translational Oncology</i> , 2011 , 13, 798-804	3.6	4
30	The European Medicines Agency review of Tegafur/Gimeracil/Oteracil (Tegsuno) for the treatment of advanced gastric cancer when given in combination with cisplatin: summary of the Scientific Assessment of the Committee for medicinal products for human use (CHMP). <i>Oncologist</i> , 2011 , 16, 1151-7	5.7	21
29	Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). <i>Annals of Oncology</i> , 2010 , 21, 1794-1803	10.3	270
28	The insulin-like growth factor pathway as a target for cancer therapy. <i>Clinical and Translational Oncology</i> , 2010 , 12, 326-38	3.6	24

27	Expression of EGFR, HER-2/neu and KIT in germ cell tumours. <i>Clinical and Translational Oncology</i> , 2010 , 12, 443-9	3.6	11
26	SEOM clinical guidelines for the treatment of advanced colorectal cancer. <i>Clinical and Translational Oncology</i> , 2010 , 12, 729-34	3.6	7
25	Inhibiting PI3K as a therapeutic strategy against cancer. <i>Clinical and Translational Oncology</i> , 2009 , 11, 572-9	3.6	26
24	Phase I/II study of gefitinib and capecitabine in patients with colorectal cancer. <i>Clinical and Translational Oncology</i> , 2008 , 10, 52-7	3.6	7
23	Prognostic value of KIT expression in small cell lung cancer. <i>Lung Cancer</i> , 2007 , 56, 405-13	5.9	37
22	Fluorouracil-based chemotherapy in patients with gastrointestinal malignancies: influence of nutritional folate status on toxicity. <i>Journal of Chemotherapy</i> , 2007 , 19, 744-9	2.3	6
21	Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. <i>Annals of Oncology</i> , 2006 , 17, 668-75	10.3	137
20	Systemic chemotherapy in the management of malignant peritoneal mesothelioma. <i>European Journal of Surgical Oncology</i> , 2006 , 32, 676-81	3.6	65
19	Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle. <i>Journal of Clinical Oncology</i> , 2005 , 23, 6107-16	2.2	77
18	Ecteinascidin-743 (ET-743) for chemotherapy-naïve patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. <i>Journal of Clinical Oncology</i> , 2005 , 23, 5484-92	2.2	152
17	Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. <i>Journal of Clinical Oncology</i> , 2004 , 22, 1480-90	2.2	247
16	A phase I trial of daily oral 4QN -benzoyl-staurosporine in combination with protracted continuous infusion 5-fluorouracil in patients with advanced solid malignancies. <i>Investigational New Drugs</i> , 2004 , 22, 139-50	4.3	25
15	A Phase I study of 9-nitrocamptothecin given concurrently with capecitabine in patients with refractory, metastatic solid tumors. <i>Cancer</i> , 2003 , 97, 148-54	6.4	11
14	Pemetrexed in bladder, head and neck, and cervical cancers. <i>Seminars in Oncology</i> , 2002 , 29, 69-75	5.5	1
13	Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity. <i>Cancer Chemotherapy and Pharmacology</i> , 2002 , 50, 309-19	3.5	55
12	Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. <i>Journal of Clinical Oncology</i> , 2002 , 20, 3772-84	2.2	222
11	Antibiotics and growth factors in the management of fever and neutropenia in cancer patients. <i>Current Opinion in Hematology</i> , 2002 , 9, 215-21	3.3	13
10	A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors. <i>Oncologist</i> , 2002 , 7, 531-8	5.7	44

9	Primary Cisplatin, Methotrexate and Vinblastine Chemotherapy With Selective Bladder Preservation for Muscle Invasive Carcinoma of the Bladder: Long-Term Followup of a Prospective Study. <i>Journal of Urology</i> , 2002 , 167, 2413-2418	2.5	15
8	Envolving treatment of fever and neutropenia in cancer patients 2002 , 4, 297-307		
7	Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. <i>Clinical Cancer Research</i> , 2002 , 8, 641-61	12.9	342
6	Plasma pharmacokinetics and bioavailability of 1-(2-chloroethyl)-3-sarcosinamide-1-nitrosourea after intravenous and oral administration to mice and dogs. <i>Cancer Chemotherapy and Pharmacology</i> , 2001 , 48, 202-8	3.5	3
5	Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. <i>Journal of the National Cancer Institute</i> , 2001 , 93, 31-8	9.7	140
4	High-dose cyclophosphamide + carboplatin and interleukin-2 (IL-2) activated autologous stem cell transplantation followed by maintenance IL-2 therapy in metastatic breast carcinoma - a phase II study. <i>Bone Marrow Transplantation</i> , 2000 , 25, 19-24	4.4	14
3	Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever. <i>Cancer</i> , 1999 , 85, 213-219	6.4	84
2	Favorable prognosis after late relapse of hodgkinQ disease 1998 , 83, 560-565		11
1	Patient selection in high-dose chemotherapy trials: relevance in high-risk breast cancer. <i>Journal of Clinical Oncology</i> , 1997 , 15, 3178-84	2.2	75